
Sensei Biotherapeutics SNSE
$ 28.19
-0.39%
Annual report 2025
added 03-30-2026
Sensei Biotherapeutics Long Term Debt Current 2011-2026 | SNSE
Annual Long Term Debt Current Sensei Biotherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.37 M | 1.59 M | 1.57 M | 1.25 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.59 M | 1.25 M | 1.44 M |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
675 K | $ 9.21 | - | $ 596 M | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
Aptorum Group Limited
APM
|
433 K | $ 0.87 | -2.13 % | $ 6.4 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
9.96 M | $ 22.43 | 1.04 % | $ 3.72 B | ||
|
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
215 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | ||
|
BioNTech SE
BNTX
|
45 M | $ 104.31 | 2.69 % | $ 27.2 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
208 K | - | -2.5 % | $ 5.88 M | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
3.25 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 3.06 | 2.34 % | $ 5.04 M | ||
|
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | ||
|
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | ||
|
Applied Therapeutics
APLT
|
429 K | - | - | $ 8.42 M | ||
|
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | ||
|
Aquestive Therapeutics
AQST
|
631 K | $ 4.08 | 0.83 % | $ 436 M | ||
|
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
2.2 M | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
538 K | - | 17.91 % | $ 11.1 M | ||
|
Arcutis Biotherapeutics
ARQT
|
294 K | $ 22.93 | 2.48 % | $ 2.92 B | ||
|
Allena Pharmaceuticals
ALNA
|
317 K | - | 3.16 % | $ 1.9 M | ||
|
Edesa Biotech
EDSA
|
19.9 K | $ 15.77 | -0.82 % | $ 50.4 M | ||
|
Athira Pharma
ATHA
|
465 K | - | - | $ 269 M | ||
|
Alpine Immune Sciences
ALPN
|
756 K | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | ||
|
Autolus Therapeutics plc
AUTL
|
4.56 M | $ 1.43 | 1.06 % | $ 381 M | ||
|
AVROBIO
AVRO
|
878 K | - | 1083.1 % | $ 745 M | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | ||
|
AstraZeneca PLC
AZN
|
382 M | - | - | $ 96.9 B | ||
|
Evogene Ltd.
EVGN
|
716 K | $ 0.76 | 0.71 % | $ 27.9 M | ||
|
Atreca
BCEL
|
3.54 M | - | -11.76 % | $ 5.79 M | ||
|
Exelixis
EXEL
|
27.9 M | $ 45.02 | 0.73 % | $ 12.2 B | ||
|
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B |